Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 12, 2017
(Exact name of registrant as specified in its charter)
Jersey, Channel Islands 0-29630 98-0601486
(State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)

Block 2

Miesian Plaza

50-58 Baggot Street Lower

Dublin 2

Republic of Ireland
(Address of principal executive offices)

Registrant’s telephone number, including area code:      +353 1 609 6000
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.):
☐  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).


Emerging growth company ☐


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐






Item 8.01. Other Events


Shire plc has issued the press release attached hereto as Exhibit 99.1 which is incorporated by reference herein.


Item 9.01. Financial Statements and Exhibits


(d) Exhibits. The following exhibit is filed herewith:


99.1       Press Release dated October 12, 2017







Exhibit No.



99.1   Press Release dated October 12, 2017






Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


  Shire plc
  By:  /s/ W R Mordan
    Name:  Bill Mordan
    Title: Company Secretary


Date: October 12, 2017




Exhibit 99.1






Shire to announce third quarter 2017 results


Dublin, Ireland – October 12, 2017 – Shire plc (LSE: SHP, NASDAQ: SHPG), will announce third quarter 2017 earnings on Friday October 27, 2017.


Results press release will be issued at: 12:00 BST / 07:00 EDT
Investor conference call time: 14:00 BST / 09:00 EDT


Live conference call for investors: 

Flemming Ornskov, MD, Chief Executive Officer, Jeff Poulton, Chief Financial Officer and Matt Walker, Head of Technical Operations will host the investor and analyst conference call at
9:00 EDT / 14:00 BST.


The details of the conference call are as follows:


UK dial in: 0808 237 0030 or 020 3139 4830
US dial in: 1 866 928 7517 or 1 718 873 9077
International Access Numbers: Click here
Password/Conf ID: 31097524#
Live Webcast: Click here



A replay of the presentation will be available for two weeks by phone and by webcast for three months. Replay information can be found on the Investor Relations section of Shire’s website at http://investors.shire.com/ .


For further information please contact:


Investor Relations    
Ian Karp ikarp@shire.com +1 781 482 9018
Robert Coates rcoates@shire.com +44 203 5490874




About Shire


Shire is the leading global biotechnology company focused on serving people with rare diseases and other highly specialized conditions. We strive to develop best-in-class products, many of which are available in more than 100 countries, across core therapeutic areas including Hematology, Immunology, Neuroscience, Ophthalmics, Lysosomal Storage Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary Angioedema; and a growing franchise in Oncology.


Our employees come to work every day with a shared mission: to develop and deliver breakthrough therapies for the hundreds of millions of people in the world affected by rare diseases and other high-need conditions, and who lack effective therapies to live their lives to the fullest.




Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX